Riboscience
1 known investors
Riboscience develops small-molecule therapeutics using ribose-based nucleoside chemistry and structure-guided design, focusing on oncology and virology. Its lead candidate is an oral ENPP1 inhibitor in Phase 2 clinical trials.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Riboscience do?
- Riboscience develops small-molecule therapeutics using ribose-based nucleoside chemistry and structure-guided design, focusing on oncology and virology. Its lead candidate is an oral ENPP1 inhibitor in Phase 2 clinical trials.
- Who are Riboscience's investors?
- Riboscience's investors include Kern Capital, LLC.